IDH1 and ATRX mutations synergistically modulate cell proliferation and ferroptosis in glioblastoma cells [0.03%]
IDH1和ATRX突变协同调节胶质母细胞瘤细胞的增殖及铁死亡
Siqi Liu,Xiangnan Xiao,Ang Li et al.
Siqi Liu et al.
IDH1 and ATRX mutations frequently co-occur in several glioma subtypes, including secondary glioblastomas (GBMs), suggesting that these alterations may function cooperatively during tumor development. However, the molecular basis of their i...
The clinicopathological features, treatment patterns, and prognosis of trichilemmal carcinoma: a retrospective case-series study [0.03%]
毛母细胞癌的临床病理特征、治疗模式和预后：基于病例系列的回顾性研究
Chuyan Shi,Bing Liu,Bo Wei et al.
Chuyan Shi et al.
Trichilemmal carcinoma (TC) is a rare malignant cutaneous appendage neoplasm originating from the epithelium of the outer root sheath of hair follicles. TC is generally non-invasive, causing only localized damage, and can be successfully ma...
Xinqiang Guo,Xuelian Xiang,Chunhong Zhuang et al.
Xinqiang Guo et al.
Advances in radiomics and machine learning techniques have facilitated the extraction of quantitative radiomic features that can be correlated with genomic data. Breast MRI-based radiogenomics, which combines MRI radiomics and genomics, is ...
Factors associated with survival in patients with spinal metastases from lung cancer [0.03%]
肺癌脊柱转移患者的生存因素分析
Wenjia Xia,Ming Li,Youtao Xu et al.
Wenjia Xia et al.
The spine is a common site for metastases in lung cancer. Precise identification of factors associated with survival and reliable prediction of prognosis are essential for clinical decision-making in patients with spinal metastasis from lun...
DERL3 exacerbates glioblastoma malignancy through endoplasmic reticulum stress-dependent mechanisms [0.03%]
DERL3通过内质网应激依赖性机制加剧胶质母细胞瘤恶性行为
Shaoqi Du,Shuo Zhang,Chen Li et al.
Shaoqi Du et al.
Gliomas, particularly glioblastoma multiforme (GBM), represent the most prevalent primary intracranial malignancies, characterized by high invasiveness, aggressive proliferation, and poor clinical outcomes. Recent studies have highlighted t...
A predictive model based on BRCA1/2, POLE, TP53, and MSH6 mutations for immunotherapy response in advanced endometrial cancer [0.03%]
基于BRCA1/2、POLE、TP53和MSH6突变的晚期子宫内膜癌免疫治疗反应预测模型
Yancai Jia,Hui Jia,Xirui Mao et al.
Yancai Jia et al.
Objective: To evaluate clinical, molecular, and immunological predictors of response to immunotherapy among patients with advanced endometrial cancer and to develop a combined biomarker model for predicting treatment outc...
Diagnostic value of combined detection of serological biomarkers in thyroid carcinoma [0.03%]
甲状腺癌血清生物标志物联合检测的诊断价值分析
Quandong Li,Ping Chen,Junjie Wan et al.
Quandong Li et al.
Objective: To evaluate the diagnostic value of combined detection of serum carcinoembryonic antigen (CEA), thyroglobulin (Tg), calcitonin (CT), and thyroid-stimulating hormone (TSH) using a chemiluminescence assay in thyr...
Erratum: Kang Ru enhances paclitaxel's efficacy against breast cancer progression [0.03%]
Correction: 英文刊头文字错误需更正
Chun-Ming Chang,Chikondi Jassi,Wei-Wen Kuo et al.
Chun-Ming Chang et al.
[This corrects the article on p. 2180 in vol. 15, PMID: 40520866.]. AJCR Copyright © 2025.
Published Erratum
American journal of cancer research. 2025 Dec 25;15(12):5394. DOI:10.62347/OYUV9080 2025
Novel therapeutic agents and intensive chemotherapy improve survival outcomes in patients with mantle cell lymphoma [0.03%]
新型治疗药物和强化疗改善了套细胞淋巴瘤患者的预后
Zi-Chi Lin,Ming-Chung Wang,Tung-Liang Lin et al.
Zi-Chi Lin et al.
Mantle cell lymphoma (MCL) is a rare type of mature B-cell lymphoma. This multicenter retrospective cohort study aimed to analyze the epidemiological characteristics, treatment patterns, and survival outcomes of patients with MCL in Taiwan....
Selinexor combined with R-GDP as salvage therapy in relapsed/refractory diffuse large B-cell lymphoma [0.03%]
塞利尼索联合R-GDP方案治疗复发/难治弥漫大B细胞淋巴瘤疗效分析
Shiyu Jiang,Youli Li,Chuanxu Liu et al.
Shiyu Jiang et al.
Relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) remains a therapeutic challenge with poor prognosis. Selinexor, a selective inhibitor of nuclear export (XPO1), has shown activity in this setting. We retrospectively evaluate...